news

Researchers discover new pathway to treat Ewing sarcoma

A study has demonstrated that blocking certain receptors in mice reduced Ewing sarcoma growth and metastasis, which could be used within future treatments.

Researchers have discovered molecular interactions which lead to the development and growth of Ewing sarcomas. They suggest that their findings could be used to develop potential treatments.

The team, from the Weizmann Institute of Science, Israel, investigated receptors for steroid hormones called glucocorticoids. These are present in almost all human cells and convey hormonal messages. However, previous studies have shown that these receptors can stimulate malignant growth by moving to the cell nucleus, where they bind and interact with transcription factors.

…seven genes which regulated the glucocorticoid receptors were expressed in higher levels in patients with particularly lethal tumours”

The researchers found that once activated by hormones, glucocorticoid receptors bound in the cell nucleus to transcription factors of the E-twenty-six (ETS) family can form another physical complex. A certain factor in the ETS family is known to drive the development of Ewing sarcoma; this gene fuses abnormally with another to produce an oncogene.  

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

An in vitro study revealed that physical binding between glucocorticoid receptors and the protein made by the oncogene increased the growth and migration of Ewing sarcoma cells. In mice models, this gene increased the growth and spread of the tumour significantly.

Using a drug used to reduce the synthesis of glucocorticoids, the scientists observed that the Ewing sarcomas grew much more slowly in the mice. Another drug which blocked the glucocorticoid receptor prevented the metastasis of the cancer.

When the researchers boosted the activity of the glucocorticoid receptors, the tumour grew and spread much faster.

The lungs of an untreated mouse with Ewing sarcoma (left) contain numerous tumor cells (shown by luminescent colors) that have spread from the bone; the lungs of a mouse treated with a drug reducing the synthesis of glucocorticoids are almost free from the disease (right) [credit: Weizmann Institute of Science].

Next, the researchers undertook a genetic analysis of tumour samples from patients with the condition. They identified seven genes which regulated the glucocorticoid receptors that were expressed in higher levels in patients with particularly lethal tumours.

The team say that these genes may serve as a genetic signature enabling the selection of patients for treatment.

“Our findings provide the basis for a personalised approach to the treatment of Ewing sarcoma,” said Dr Swati Srivastava, one of the lead researchers.

The results were published in Cell Reports.

Leave a Reply

Your email address will not be published. Required fields are marked *